Home Biosimilar Antibodies Immunology & Inflammation CD markers Dapirolizumab (Anti-TNFSF5 / CD40L / CD154)
For research use only. Not for use in humans.

Dapirolizumab (Anti-TNFSF5 / CD40L / CD154)

Synonyms: null

Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa.

Dapirolizumab (Anti-TNFSF5 / CD40L / CD154)

Quality Control

Batch: A231301 Purity: 99% Protein concentration: 9.33mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa.

Product Details

Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04976322 ENROLLING_BY_INVITATION Drug: Dapirolizumab pegol Systemic Lupus Erythematosus UCB Biopharma SRL 2021-07-27 PHASE3
NCT07204080 NOT_YET_RECRUITING Drug: TNX-1500 Kidney Transplant; Kidney Transplant Failure and Rejection; Immunosuppression; Immunosuppression After Kidney Transplantation Ayman Al Jurdi, MD 2026-11-01 PHASE2
NCT06961357 RECRUITING Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Interleukin-2 Melanoma H. Lee Moffitt Cancer Center and Research Institute 2025-12-03 PHASE1; PHASE2
NCT06305286 ACTIVE_NOT_RECRUITING Drug: Islet transplantation with Tegoprubart (AT-1501) immun Type 1 Diabetes Mellitus University of Chicago 2024-03-04 PHASE1; PHASE2
NCT06617325 RECRUITING Drug: DZP Systemic Lupus Erythematosus UCB Biopharma SRL 2024-11-21 PHASE3
NCT06959771 RECRUITING Drug: Alemtuzumab|Drug: Sirolimus|Drug: Palifermin|Drug: Bus CD40L-HyperIgM Syndrome National Institute of Allergy and Infectious Diseases (NIAID) 2025-07-16 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.